These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 14727208

  • 1. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW.
    Clin Infect Dis; 2004 Feb 01; 38(3):377-83. PubMed ID: 14727208
    [Abstract] [Full Text] [Related]

  • 2. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW.
    N Engl J Med; 2010 Feb 11; 362(6):504-12. PubMed ID: 20147716
    [Abstract] [Full Text] [Related]

  • 3. What is the current and future status of conventional amphotericin B?
    Kleinberg M.
    Int J Antimicrob Agents; 2006 Jun 11; 27 Suppl 1():12-6. PubMed ID: 16707251
    [Abstract] [Full Text] [Related]

  • 4. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S, Mehta H, Chhabra A, Singh V, Chauhan V, Desjeux P, Rai M.
    Clin Infect Dis; 2006 Mar 01; 42(5):608-13. PubMed ID: 16447104
    [Abstract] [Full Text] [Related]

  • 5. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F, Videla S, Jiménez-Mejías ME, Sirera G, Torre-Cisneros J, Ribera E, Prados D, Clotet B, Sust M, López-Vélez R, Alvar J, Spanish HIV-Leishmania Study Group.
    J Antimicrob Chemother; 2003 Sep 01; 52(3):464-8. PubMed ID: 12888588
    [Abstract] [Full Text] [Related]

  • 6. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.
    Meheus F, Boelaert M, Baltussen R, Sundar S.
    Trop Med Int Health; 2006 Nov 01; 11(11):1715-24. PubMed ID: 17054752
    [Abstract] [Full Text] [Related]

  • 7. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R.
    Clin Infect Dis; 2003 Sep 15; 37(6):800-4. PubMed ID: 12955641
    [Abstract] [Full Text] [Related]

  • 8. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
    Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW.
    Clin Infect Dis; 2007 Sep 01; 45(5):556-61. PubMed ID: 17682988
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD.
    Bull World Health Organ; 1998 Sep 01; 76(1):25-32. PubMed ID: 9615494
    [Abstract] [Full Text] [Related]

  • 10. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.
    Amato VS, Tuon FF, Campos A, Bacha HA, Nicodemo AC, Amato Neto V, Shikanai-Yasuda MA.
    Clin Infect Dis; 2007 Jan 15; 44(2):311-2. PubMed ID: 17173238
    [No Abstract] [Full Text] [Related]

  • 11. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.
    Clin Infect Dis; 2008 Oct 15; 47(8):1000-6. PubMed ID: 18781879
    [Abstract] [Full Text] [Related]

  • 12. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G.
    Int J Antimicrob Agents; 2005 Jan 15; 25(1):26-30. PubMed ID: 15620822
    [Abstract] [Full Text] [Related]

  • 13. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM, Lumbreras C, González-Vidal D, Grupo de Farmacovigilancia de Abelcet.
    Clin Microbiol Infect; 2004 Sep 15; 10(9):785-90. PubMed ID: 15355408
    [Abstract] [Full Text] [Related]

  • 14. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.
    N Engl J Med; 2007 Jun 21; 356(25):2571-81. PubMed ID: 17582067
    [Abstract] [Full Text] [Related]

  • 15. Antileishmanial activity of nano-amphotericin B deoxycholate.
    Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S.
    J Antimicrob Chemother; 2008 Aug 21; 62(2):376-80. PubMed ID: 18453526
    [Abstract] [Full Text] [Related]

  • 16. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
    Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M.
    Trop Med Int Health; 2008 Sep 21; 13(9):1208-12. PubMed ID: 18664241
    [Abstract] [Full Text] [Related]

  • 17. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
    Barcia JP.
    Pharmacotherapy; 1998 Sep 21; 18(4):874-6. PubMed ID: 9692667
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
    Minodier P, Robert S, Noël G, Blanc P, Retornaz K, Garnier JM.
    Arch Pediatr; 2005 Jul 21; 12(7):1102-8. PubMed ID: 15964525
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
    Borges MM, Pranchevicius MC, Noronha EF, Romero GA, Carranza-Tamayo CO.
    Rev Soc Bras Med Trop; 2017 Jul 21; 50(1):67-74. PubMed ID: 28327804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.